改良氟尿嘧啶、亚叶酸钙、奥沙利铂和伊立替康联合帕尼单抗对比氟尿嘧啶、亚叶酸钙和奥沙利铂联合帕尼单抗一线治疗RAS/BRAF野生型转移性结直肠癌:GONO开展的III期TRIPLETE研究
TRIPLETE研究为前瞻性、开放标签、III期试验,将435例不可切除的RAS和BRAF野生型转移性结直肠癌初治患者按1:1随机分配至改良FOLFOX/帕尼单抗组或mFOLFOXIRI/帕尼单抗组,最多12个周期,后续氟尿嘧啶/亚叶酸钙/帕尼单抗直至疾病进展。主要终点客观缓解率在两组间无显著差异(73% vs 76%,比值比0.87,95%CI 0.56-1.34,P=0.526),无进展生存期亦无显著差异(中位12.7 vs 12.3个月,风险比0.88,95%CI 0.70-1.11,P=0.277)。
要点
- mFOLFOXIRI联合帕尼单抗对比改良FOLFOX联合帕尼单抗未提高客观缓解率(73% vs 76%,P=0.526)。
- 两组中位无进展生存期无显著差异(12.7 vs 12.3个月,HR 0.88,95%CI 0.70-1.11,P=0.277)。
- 强化化疗方案伴随胃肠道毒性增加。
核心结论
- 在RAS和BRAF野生型转移性结直肠癌患者中,一线化疗骨架强化联合帕尼单抗未在治疗活性方面提供额外获益,代价是胃肠道毒性增加。
研究设计与样本
- TRIPLETE为前瞻性、开放标签、III期试验,纳入既往未治疗的不可切除RAS和BRAF野生型转移性结直肠癌患者,按1:1随机分配至改良FOLFOX/帕尼单抗组(对照组)或mFOLFOXIRI/帕尼单抗组(试验组),最多12个周期,后续氟尿嘧啶/亚叶酸钙/帕尼单抗直至疾病进展。
- 2017年9月至2021年9月,意大利57个中心共入组435例患者(对照组217例,试验组218例)。
- 主要终点为根据RECIST 1.1评估的客观缓解率;假设对照组客观缓解率为60%,432例可提供90%把握度,双侧卡方异质性检验,双侧α误差0.05,检测组间≥15%差异。
主要发现
- mFOLFOXIRI联合帕尼单抗组160例(73%)和改良FOLFOX联合帕尼单抗组165例(76%)达到RECIST缓解(比值比0.87,95%CI 0.56-1.34,P=0.526)。
- 早期肿瘤缩小率(57%/58%,P=0.878)和缓解深度(中位48%/47%,P=0.845)无差异,R0切除率(25%/29%,P=0.317)亦无差异。
- 中位无进展生存期试验组12.7个月对比对照组12.3个月(风险比0.88,95%CI 0.70-1.11,P=0.277),两组间无显著差异。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To verify whether the intensification of the upfront chemotherapy backbone with a modified schedule of modified fluorouracil, leucovorin, oxaliplatin, and irinotecan (mFOLFOXIRI) increases the activity of fluorouracil, leucovorin, and oxaliplatin when both regimens are combined with panitumumab as initial treatment for RAS and BRAF wild-type (wt) metastatic colorectal cancer (mCRC). METHODS: TRIPLETE was a prospective, open-label, phase III trial in which previously untreated patients with unresectable RAS and BRAF wt mCRC were randomly assigned 1:1 to modified FOLFOX/panitumumab (control group) or mFOLFOXIRI/panitumumab (experimental group) up to 12 cycles, followed by fluorouracil/-leucovorin/panitumumab until disease progression. The primary end point was objective response rate (ORR) according to RECIST 1.1. Hypothesizing an ORR of 60% in the control group, 432 cases provided 90% power to a two-sided chi-square test for heterogeneity with a two-sided alpha error of .05 to detect ≥ 15% differences between arms (ClinicalTrials.gov identifier: NCT03231722). RESULTS: From September 2017 to September 2021, 435 patients were enrolled (control group/experimental group: 217/218) in 57 Italian sites. One hundred sixty (73%) patients treated with mFOLFOXIRI plus panitumumab and 165 (76%) patients treated with modified FOLFOX plus panitumumab achieved RECIST response (odds ratio 0.87, 95% CI, 0.56 to 1.34, P = .526). No differences in early tumor shrinkage rate (57%/58%, P = .878) and deepness of response (median: 48%/47%, P = .845) were reported, nor in R0 resection rate (25%/29%, P = .317). No significant difference between arms was reported in terms of progression-free survival (median progression-free survival: 12.7 in the experimental group v 12.3 months in the control group, hazard ratio: 0.88, 95% CI, 0.70 to 1.11, P = .277). CONCLUSION: The intensification of the upfront chemotherapy backbone in combination with panitumumab does not provide additional benefit in terms of treatment activity at the price of increased gastrointestinal toxicity in patients with RAS and BRAF wt mCRC.
引用
- Rossini D, Antoniotti C, Lonardi S, et al. Upfront Modified Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan Plus Panitumumab Versus Fluorouracil, Leucovorin, and Oxaliplatin Plus Panitumumab for Patients With RAS/BRAF Wild-Type Metastatic Colorectal Cancer: The Phase III TRIPLETE Study by GONO. J Clin Oncol. 2022. PMID: 35666229. doi:10.1200/JCO.22.00839
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。